If you are wondering whether Bristol-Myers Squibb is quietly becoming a value opportunity or just a classic value trap, you ...

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after an analyst at ...

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...

Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in ...

Emerging evidence hints that daily multivitamins might quietly help certain older adults keep their blood pressure in ...

Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.

Fintel reports that on December 12, 2025, Guggenheim upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Neutral ...

An artificial intelligence-based endoscopic scoring system may better reflect symptoms and quality of life in ulcerative ...

Fintel reports that on December 12, 2025, Morgan Stanley maintained coverage of Bristol-Myers Squibb Company - Preferred Security (OTCPK:BMYMP) with a Underweight recommendation. Analyst Price ...

Neutral sector-focused overview describing factual commentary surrounding Bristol Myers Squibb within the wider ...

Bristol-Myers Squibb faces patent cliff risks despite strong drug revenues and a 4.8% yield. Click here to read my latest analysis of BMY stock.

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for ...